Home » Stocks » EYES

Second Sight Medical Products, Inc. (EYES)

Stock Price: $5.55 USD -0.28 (-4.80%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $5.38 -0.17 (-3.06%) May 7, 7:52 PM
Market Cap 154.90M
Revenue (ttm) 497,000
Net Income (ttm) -14.88M
Shares Out 27.91M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $5.55
Previous Close $5.83
Change ($) -0.28
Change (%) -4.80%
Day's Open 5.70
Day's Range 5.18 - 6.24
Day's Volume 10,360,968
52-Week Range 0.69 - 20.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Short-covering has become one of the hottest buzzwords of the year. Here are 5 stocks with some of the highest shorts on the market.

Other stocks mentioned: BLNK, FUV, OTRK, ROOT
3 weeks ago - InvestorPlace

Investors are clamoring to find the next GameStop. Of the most shorted stocks right now, these are the candidates most primed for a squeeze.

Other stocks mentioned: AMC, BLNK, CHPT
4 weeks ago - InvestorPlace

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended t...

1 month ago - Business Wire

Termination of the business combination with Second Sight Medical Products, Inc.

1 month ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended t...

1 month ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended t...

1 month ago - Business Wire

Second Sight Will Probably Take a Second Look at Giving Up Control. EYES stock will probably rise if the company backs off of the sale of 60% to Pixium Vision.

1 month ago - InvestorPlace

Add in the pending capital raise, and dilution concerns are on the table as well. Speculative mania over low-priced stocks may help it hold onto most of its gains.

1 month ago - InvestorPlace

Livexlive Media Inc (NASDAQ: LIVX) shares are trading higher after the company announced it's launching a series of pay-per-view shows on Facebook's new paid online event feature spanning comedy, sports...

Other stocks mentioned: LIVX
1 month ago - Benzinga

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES), (the "Company" or "Second Sight"), a leading developer and marketer of implantable visual prosthetics that are intended ...

1 month ago - Business Wire

EYES stock jumped higher off a very encouraging FDA approval but now is the time to apply a little more scrutiny to the Second Sight Medical investment. The post Second Sight Medical Products Is No Shor...

1 month ago - InvestorPlace

You won't believe your eyes when you see the ultra-bullish price action in EYES stock, along with the game-changing regulatory announcement. The post FDA Approval Sheds New Light on Second Sight Medical...

1 month ago - InvestorPlace

Paris, France, March 09, 2021 – Pixium Vision (Euronext Growth Paris - FR0011950641) announces that the business combination with Second Sight Medical Products, Inc. (« Second Sight ») (Nasdaq: EYES) co...

1 month ago - GlobeNewsWire

Second Sight Medical Products Inc (NASDAQ: EYES) shares have soared above 723% over the previous two trading sessions with the stock touching an intraday high of $14.83 on Monday. The shares registered ...

1 month ago - Benzinga

Second Sight Medical Products (EYES) stock just can't stop soaring higher following approval from the FDA on Friday for one of its devices. The post EYES Stock: 12 Things for Second Sight Medical Invest...

1 month ago - InvestorPlace

So what did the stock market do today? We watched a major turnaround in the stock market and saw a few winners and losers emerge.

Other stocks mentioned: NCLH, SPCE
2 months ago - InvestorPlace

Second Sight (EYES) stock is soaring higher Friday after announcing approval from the FDA for its Argus 2s Retinal Prosthesis System. The post EYES Stock: The Big FDA News That Has Second Sight Shares S...

2 months ago - InvestorPlace

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful visi...

2 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form o...

7 months ago - Business Wire

Markets took off this morning following more good news regarding coronavirus vaccines. Less-than-good earnings are expected for corporations, but it doesn't seem that way when looking at the major three...

Other stocks mentioned: APVO, BLNK, EFOI, SGBX
9 months ago - Forbes

If you're wondering how markets are still surging in light of record-breaking coronavirus cases, our deep learning algorithms paired with Artificial Intelligence (“AI”) technology has you covered with t...

Other stocks mentioned: BHF, JAGX, RMBL, SLNO
9 months ago - Forbes

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead of itself.

Other stocks mentioned: BKYI, COCP, EYPT, REPH
10 months ago - Forbes

Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

11 months ago - Zacks Investment Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

Second Sight Medical Products' (EYES) CEO Will McGuire on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 4.08% and -40.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...

1 year ago - Zacks Investment Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Second Sight Medical Products, Inc's (EYES) CEO Will McGuire on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and -49.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for t...

1 year ago - Zacks Investment Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Second Sight Medical Products, Inc. (EYES) CEO Will McGuire on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and 183.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the st...

1 year ago - Zacks Investment Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Second Sight Medical Products, Inc. (EYES) CEO Jonathan McGuire on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of -66.67% and -33.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the...

1 year ago - Zacks Investment Research

Second Sight Medical Products, Inc. (EYES) CEO Will McGuire on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About EYES

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injur... [Read more...]

Industry
Medical Devices
IPO Date
Nov 19, 2014
Stock Exchange
NASDAQ
Ticker Symbol
EYES
Full Company Profile

Financial Performance

Financial Statements